CRVO
$4.53
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosse...
Recent News
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.